Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors

被引:132
作者
Kim, TW
Lee, HN
Kang, YK
Choe, MS
Ryu, MH
Chang, HM
Kim, JS
Yook, JH
Kim, BS
Lee, JS
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Hematol Oncol Sect,Dept Med, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Diagnost Pathol, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea
关键词
D O I
10.1158/1078-0432.CCR-03-0581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic signifi-cance of e-kit mutations, however, is still controversial. Experimental Design: We examined 86 patients cura-tively resected for localized GIST. Genomic DNA was extracted from paraffin-embedded tumor tissues. Exons 9, 11, 13, and 17 of the c-kit gene were amplified by PCR and sequenced. Results: Mutations in exon 11 were detected in 61 tumors, and mutations in exon 9 were observed in three tumors, whereas no mutations were detected in exons 13 or 17. The overall c-kit mutation frequency was 74%. Amino acid alterations in the 61 tumors with exon 11 mutations were deletion in 33 tumors, substitution in 20, both deletion and substitution in 4, insertion in 1, and duplication in 3. Histo-logically, tumors with c-kit mutations showed higher mitotic counts and higher cellularity. The 5-year relapse-free survival (RFS) in patients having GISTs with c-kit mutations was 21%, compared with 60% in those without c-kit mutations. Significantly higher RFS rates were observed in patients with tumors having mitotic counts < 5 mitoses/50 high power field, spindle-cell histology, tumor size < 5 cm, or gastric GISTs. Multivariate analyses indicated association of poorer RFS with a higher mitotic count [ greater than or equal to5 of 50 high power fields; odds ratio (OR) = 3.0], presence of c-kit mutations (OR = 5.6), and a larger tumor size (greater than or equal to5 cm; OR = 4.2). Conclusions: The presence of c-kit mutation, along with high mitotic count and larger tumor size, was an independent factor for poor prognosis in patients with localized GISTs.
引用
收藏
页码:3076 / 3081
页数:6
相关论文
共 26 条
[1]  
Appelman H D, 1990, Monogr Pathol, P220
[2]   Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors [J].
Carrillo, R ;
Candia, A ;
RodriguezPeralto, JL ;
Caz, V .
HUMAN PATHOLOGY, 1997, 28 (02) :160-165
[3]   KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size [J].
Corless, CL ;
McGreevey, L ;
Haley, A ;
Town, A ;
Heinrich, MC .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) :1567-1572
[4]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[5]  
Ernst SI, 1998, LAB INVEST, V78, P1633
[6]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465
[7]   DIFFERENTIATION AND RISK ASSESSMENT OF GASTROINTESTINAL STROMAL TUMORS [J].
FRANQUEMONT, DW .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 103 (01) :41-47
[8]   PDGFRA activating mutations in gastrointestinal stromal tumors [J].
Heinrich, MC ;
Corless, CL ;
Duensing, A ;
McGreevey, L ;
Chen, CJ ;
Joseph, N ;
Singer, S ;
Griffith, DJ ;
Haley, A ;
Town, A ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
SCIENCE, 2003, 299 (5607) :708-710
[9]   Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].
Heinrich, MC ;
Corless, CL ;
Demetri, GD ;
Blanke, CD ;
von Mehren, M ;
Joensuu, H ;
McGreevey, LS ;
Chen, CJ ;
Van den Abbeele, AD ;
Druker, BJ ;
Kiese, B ;
Eisenberg, B ;
Roberts, PJ ;
Singer, S ;
Fletcher, CDM ;
Silberman, S ;
Dimitrijevic, S ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349
[10]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580